Perpetual Ltd Boosts Stake in BioMarin Pharmaceutical

The institutional investor increased its holdings in the biotech firm by over 400% in Q4 2025.

Apr. 5, 2026 at 9:33am

Got story updates? Submit your updates here. ›

Perpetual Ltd, an institutional investor, significantly increased its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) during the fourth quarter of 2025. According to a recent 13F filing with the SEC, Perpetual Ltd now owns 25,621 shares of the biotechnology company's stock, up 425.7% from the previous quarter.

Why it matters

This substantial increase in Perpetual Ltd's BioMarin holdings suggests the investor sees strong growth potential in the biotech firm, which develops therapies for rare genetic and metabolic diseases. The move could signal broader investor confidence in BioMarin's pipeline and commercial prospects.

The details

Perpetual Ltd purchased an additional 20,747 shares of BioMarin Pharmaceutical during the fourth quarter, bringing its total holdings to 25,621 shares. The institutional investor's stake in the biotech company is now valued at $1.523 million as of the latest SEC filing.

  • Perpetual Ltd increased its BioMarin holdings during the fourth quarter of 2025.
  • The 13F filing detailing Perpetual Ltd's increased stake was published on April 5, 2026.

The players

Perpetual Ltd

An institutional investor that significantly increased its stake in BioMarin Pharmaceutical Inc. during the fourth quarter of 2025.

BioMarin Pharmaceutical Inc.

A biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases.

Got photos? Submit your photos here. ›

The takeaway

Perpetual Ltd's substantial increase in its BioMarin Pharmaceutical holdings suggests growing investor confidence in the biotech firm's ability to develop successful rare disease treatments and drive future growth.